1. Hicks, LA, Bartoces, MG, Roberts, RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015;60:1308–1316.
2. MacDougall, C, Polk, RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008;29:203–211.
3. Spellberg, B, Guidos, R, Gilbert, D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155–164.
4. Dellit, TH, Owens, RC, McGowan, JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159–177.
5. Gerber, JS, Newland, JG, Coffin, SE, et al. Variability in antibiotic use at children’s hospitals. Pediatrics 2010;126:1067–1073.
6. Polk, RE, Hohmann, SF, Medvedev, S, Ibrahim, O. Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals. Clin Infect Dis 2011;53:1100–1110.
7. Kanerva, M, Ollgren, J, Lyytikainen, O, Finnish Prevalence Survey Study Group. Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment. J Antimicrob Chemother 2011;66:2651–2654.
8. Tan, C, Vermeulen, M, Wang, X, Zvonar, R, Garber, G, Daneman, N. Variability in antibiotic use across Ontario acute care hospitals. J Antimicrob Chemother 2017;72:554–563.
9. Kronman, MP, Gerber, JS, Prasad, PA, et al. Variation in antibiotic use for children hospitalized with inflammatory bowel disease exacerbation: a multicenter validation study. J Pediatr Infect Dis Soc 2012;1:306–313.
10. Fisher, BT, Gerber, JS, Leckerman, KH, et al. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia Lymphoma 2013;54:1633–1639.
11. Peled, JU, Jenq, RR, Holler, E, van den Brink, MR. Role of gut flora after bone marrow transplantation. Nat Microbiol 2016;1:16036.
12. Weber, D, Jenq, RR, Peled, JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 2017;23:845–852.
13. Fisher, BT, Sammons, JS, Li, Y, et al. Variation in risk of hospital-onset clostridium difficile infection across beta-lactam antibiotics in children with new-onset acute lymphoblastic leukemia. J Pediatr Infect Dis Soc 2014;3:329–335.
14. Downes, KJ, Cowden, C, Laskin, BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatr 2017;171:e173219.
15. Trifilio, S, Verma, A, Mehta, J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transpl 2004;33:735–739.
16. Whangbo, J, Ritz, J, Bhatt, A. Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2017;52:183–190.
17. Freifeld, AG, Bow, EJ, Sepkowitz, KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56–e93.
19. Arnold, SD, Brazauskas, R, He, N, et al. Role of donor source on clinical outcomes and inpatient resource utilization for hematopoietic cell transplantation in children with acute leukemia. Blood 2016;128:1.
20. Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2014.
21. Fridkin, SK, Steward, CD, Edwards, JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999;29:245–252.
22. Winestone, LE, Getz, KD, Miller, TP, et al. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. Am J Hematol 2017;92:141–148.
23. Wilkes, JJ, Hennessy, S, Xiao, R, et al. Volume-outcome relationships in pediatric acute lymphoblastic leukemia: association between hospital pediatric and pediatric oncology volume with mortality and intensive care resources during initial therapy. Clin Lymphoma Myeloma Leuk 2016;16:404–410.
24. Getz, KD, Miller, TP, Seif, AE, et al. Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children’s Oncology Group report. Cancer Med 2016;5:2412–2416.
25. Maude, SL, Fitzgerald, JC, Fisher, BT, et al. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med 2014;15:112–120.
26. Wolf, J, Sun, Y, Tang, L, et al. Antimicrobial stewardship barriers and goals in pediatric oncology and bone marrow transplantation: a survey of antimicrobial stewardship practitioners. Infect Control Hosp Epidemiol 2016;37:343–347.
27. Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.
28. Yeo, CL, Chan, DS, Earnest, A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2012;31:583–590.
29. Azap, A, Topcuoglu, P, Yesilkaya, A, et al. The effect of a nationwide antibiotic restriction policy on antibiotic usage in a stem cell transplantation unit. Turk J Haematol 2005;22:87–90.
30. Saito, T, Yoshioka, S, Iinuma, Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis 2008;27:209–216.
31. Hughes, WT, Armstrong, D, Bodey, GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.
32. Taur, Y, Jenq, RR, Perales, MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014;124:1174–1182.
33. Shono, Y, Docampo, MD, Peled, JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Translat Med 2016;8:339ra371–339ra371.
34. Peled, JU, Devlin, SM, Staffas, A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncology 2017;35:1650–1659.
35. Antin, JH. Relationship between intestinal bacteria and the anticancer effect of hematopoietic stem-cell transplantation. J Clin Oncology 2017;35:1636–1637.
36. Staffas, A, Burgos da Silva, M, van den Brink, MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 2017;129:927–933.
37. Grohskopf, LA, Huskins, WC, Sinkowitz-Cochran, RL, et al. Use of antimicrobial agents in United States neonatal and pediatric intensive care patients. Pediatr Infect Dis J 2005;24:766–773.
38. Courter, JD, Parker, SK, Thurm, C, et al. Accuracy of administrative data for antimicrobial administration in hospitalized children. J Pediatric Infect Dis Soc 2017. doi: 10.1093/jpids/pix064.